Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 5/20 | 0.50 |
| ▸ | MME | P08473 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 12/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.44 |
| ▸ | IL1B | P01584 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6631460 | 0.91 | CASP1 (0.48) | CASP1MMEACELCKCASP3 | |
| SCHEMBL6629120 | 0.90 | CASP3 (0.48) | CASP1MMEACELCKCASP3 | |
| SCHEMBL6629124 | 0.90 | CASP3 (0.48) | CASP1MMEACELCKCASP3 | |
| SCHEMBL6627304 | 0.89 | LCK (0.48) | CASP1MMEACELCKIL1B | |
| SCHEMBL6627306 | 0.89 | LCK (0.48) | CASP1MMEACELCKIL1B | |
| SCHEMBL6629068 | 0.88 | CASP3 (0.44) | CASP1MMEACELCKCASP3 | |
| SCHEMBL6629071 | 0.88 | CASP3 (0.44) | CASP1MMEACELCKCASP3 | |
| SCHEMBL6627545 | 0.88 | LCK (0.47) | CASP1MMEACELCK | |
| SCHEMBL6627543 | 0.88 | LCK (0.47) | CASP1MMEACELCK | |
| SCHEMBL6629773 | 0.87 | CASP1 (0.44) | CASP1MMEACELCKCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1246824-B1 | CARBOXAMIDE DIAZEPIN DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2004-06-09 | — | — | EP | claimed |
| US-20030100550-A1 | Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof | AVENTIS PHARMA S.A. (FR) | 2003-05-29 | — | — | US | claimed |
| EP-1246824-B1 | CARBOXAMIDE DIAZEPIN DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100550-A1 | Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof | HRH4, HRH3, HRH2 | CASP1 2506/4885MME 2031/4885ACE 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.